Navigation Links
New therapies harness power of the immune system against cancer
Date:6/2/2014

CHICAGO New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments used alone or in combination fight cancer by activating and amplifying the body's immune response to the disease.

The new studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease. In addition, another small trial reports that a one-time, personalized immunotherapy treatment induces complete and long-lasting remissions in a small number of women with advanced cervical cancer a disease with little to no effective treatment options.

"The field of immunotherapy has exploded in the last decade, and more and more patients are benefiting," said press briefing moderator Steven O'Day, MD, ASCO expert and clinical associate professor of medicine at the University of Southern California, Keck School of Medicine. "Having a potential new way to keep melanoma at bay is a major advance for patients who live under the constant fear of recurrence after surgery. It's also incredibly exciting that we're extending the benefits of immunotherapy beyond melanoma, to diseases like cervical cancer where patients urgently need better options."

Featured studies include:

  • Adjuvant ipilimumab improves recurrence-free survival in patients with high-risk stage III melanoma: Study marks the first time adjuvant (post-surgery) ipilimumab is shown to be effective in earlier-stage melanoma, though side effects are considerable.

  • PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma: Large phase I trial finds high survival rates in patients with advanced melanoma, including those previously treated with ipilimumab; one-year survival rate is 69 percent across all patient subgroups.

  • Combination immunotherapy with ipilimumab and nivolumab achieves long-term survival for patients with advanced melanoma: Updated follow-up data from an expanded phase I study show concurrent treatment with ipilimumab and the anti-PD-1 nivolumab yields strong, long-lasting responses and high survival rates.

  • HPV-targeted adoptive T cell therapy may provide a new personalized strategy for advanced cervical cancer: Early study of HPV-targeted immunotherapy shows promising activity in metastatic cervical cancer, a hard-to-treat disease with few effective treatment options.


'/>"/>

Contact: Kate Blackburn
Kate.Blackburn@asco.org
312-949-3232
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Study examines adverse effects among different radiation therapies for prostate cancer
2. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
3. Doubt Cast on Usefulness of Sensory Therapies for Autism
4. Student researchers seek to develop new therapies for cancer
5. New Therapies Show Some Promise Against Pancreatic Cancer
6. University of Nevada School of Medicine researcher reviews muscular dystrophy therapies
7. Well-known author and historian reports on progress in Huntingtons therapies
8. Scientists develop mouse model that could lead to new therapies for liver cancer
9. $53 million grant will help health researchers develop new therapies -- with the publics help
10. New method may allow personalized clinical trial for cancer therapies
11. By studying animal health, researchers find improved ways for developing, testing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Franklin, TN (PRWEB) , ... May 26, 2016 , ... ... today, and more than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, ... the 29th annual National Cancer Survivors Day®. , National Cancer Survivors Day® is ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... , ... May 26, 2016 , ... North Cypress ... 13 at Blackhorse Golf Club in Cypress. With the help of community partners, the ... restores, empowers, and renews hope for wounded service members and their families through health, ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... products recently hosted the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The ... group of fitness professional through the 8 hour interactive course to qualify participants ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes coincides with ... ™”. , “We are proud to introduce Meghan Klingenberg, defender and World ... Brian Quick, wide receiver for Los Angeles who was a second round selection in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
Breaking Medicine Technology: